Phenylalanine compounds

Abstract

Phenylalanine compounds of the formula : WHEREIN : X is hydrogen, halogen, methyl, ethyl or trifluoromethyl, and Het is hexamethyleneimino, piperidino, methylpiperidino, dimethylpiperidino or azabicycloalkyl containing from 5 to 8 carbon atoms, each bonded to the phenyl nucleus by its nitrogen atom. These compounds are used as medicines in the treatment of central nervous system disorders and alcoholism.

Claims

1. A COMPOUND SELECTED FROM THE GROUP CONSISTING OF (A) PHENYLALANINE COMPOUNDS OF THE GENERAL FORMULA: 2. A compound of claim 1 which is para-hexamethyleneimino phenylalanine.
United States Patent [1 1 Beregi et al. I451 Jan.7, 1975 l PHENYLALANINE COMPOUNDS [75] Inventors: Laszlo Beregi, Boulogne S/Seine; Pierre Hugon, Ru Eil-Malmaison; Jacques Duhault, Chatou; Jean-Claude Poignant, Bures S/Yvette, all of France [731 Assignee: Science Union Et Cie, Societe Francaise De Recherche Medicale, Suresnes, France 22] Filed: Feb. 16, 1973 21 Appl. No: 333,094 [30] Foreign Application Priority Data Mar. 6, 1972 Great Britain 10365/72 [52] US. Cl. 260/239 BF, 260/240 F, 260/293.78, 260/326.32, 424/244, 424/267, 424/274 [51] Int. CL. C07d 27/30, C07d 29/28, CO7d 41/04 [58] Field of Search... 260/239 BF, 326.32, 326.41, 260/29378 [5 6] References Cited OTHER PUBLICATIONS Bergel et al., Chemical Abstracts, Vol. 53, columns 1220142203, (1959), QDlASl. Harper et al., Chemical Abstracts, Vol. 45, Column 7193, (1951), QDIASl. Abshire, Chemical Abstracts, Vol. 70, Abstract No. 47822(e), (1970), QDIASI. Primary Examiner-Alt0n D. Rollins Attorney, Agent, or Firm-Omri M. Behr [57] ABSTRACT Phenylalanine compounds of the formula These compounds are used as medicines in the treatment of central nervous system disorders and alcoholism. 2 Claims, N0 Drawings PHENYLALANINE COMPOUNDS The present invention provides phenylalanine compounds of the general formula I: HetQ- cs CH coon I l NH2 and basic addition salts, especially physiologically tolerable basic addition salts thereof. As bases which may be used to form physiologically tolerable addition salts, there may be especially mentioned alkaline metal hydroxides such as sodium and potassium hydroxides. The compounds of the general formula I are new and they are prepared by reacting a benzaldehyde of the general formula II: Het @0110 wherein X and Het have the meaningsgiven above, with hippuric acid: CO NH CH COOH in the presence of acetic anhydride and sodium acetate, then treating the so-obtained oxazolone of the general formula III: III wherein X and Het have the meanings given above, with hydriodic acid and'phosphorus. The oxazolones of the general formula Ill are also new compounds which may be used as intermediates or starting materials in the chemical and the pharmaceutic'al industries. The compounds of the general formula I and physiologically tolerable addition salts thereof possess valuable pharmacological and therapeutic properties, especially they possess an inhibiting action on the central nervous system and they antagonize the effect of alcohol; so they may be used as medicines, especially in the treatment ofcentral nervous system disorders and alcoholism. The present invention also provides a pharmaceutical preparation containing a compound of the general formula l or a physiologically tolerable basic addition salt thereof in admixture or conjunction with a pharmaceutically acceptable carrier such for example as: distilled water. glucose, lactose, starch. talc. ethylccllulosc. magnesium stearate or cocoa butter. The pharmaceutical forms may be tablets, dragccs. capsules, suppositories or injectable solutions, and may be administered by oral, rectal or parenteral route at the dose of from 10 to 100 mg. The following examples illustrate the invention. The parts are by weight and the melting points were determined on the Kofler block (K) or on the Kofler heater under a microscope (MK). EXAMPLE 1 Para-hexamethyleneimino phenylalanine I N ca CH coon I 60 parts of acetic anhydride were added to 100 parts of hydriodic acid (d 1.7), cooled by iced-water, in the course of 15 minutes. 12 parts of red phosphorus and 14 parts of 2-phenyl-4-(para-hexamethyleneimino benzylidene)-5-oxazolone were added to the resulting solution. The reaction mixture was refluxed for one and a half hours and was then cooled and diluted with parts of water. The phosphorus was filtered off and the filtrate was evaporated in vacuo. The residue was teken up with 200 parts of boiling water, was alkalinized with 20 parts of concentrated NH OH, and the solid obtained was filtered off and was then dried. There were obtained 8.6 parts of para-hexamethyleneimino phenyl alanine, hemihydrate, after recrystallisation from water; M.P. (MK) 167-l68 C. The starting 2-phenyl-4-(para-hexamethyleneimino benZylidene)-5-oxazolone was prepared as follows: 14.3 parts of hippuric acid, 24 parts of acetic anhydride and 6.6 parts of fused and powdered sodium acetate were added to 16.3 parts of parahexamethyleneimino benzaldehyde. The reaction mixture was heated on a steam-bath at C; an exothermic reaction took place, the heating was stopped and the internal temperature rose to 118 C. After completion of the reaction, the mixture was heated at 100 C for 30 minutes. The mixture was then cooled and there were added 40 parts of water and 40 parts of ether. The precipitated solid was filtered and recrystallized from cyclohexane to give 2-phenyl-4-(parahexamethyleneimino benzylidene)-5-oxazolone, M.P. (K) 154 C. EXAMPLES 2 to 5 The following compounds were prepared by the method described in Example 1. 2. Para-piperidino phenylalanine, M.P. (MK) l92l95 C (H O), starting from 2-phenyl-4-(para- 3 piperidino benzylidene)--oxazolone, M.P. (K) 167 C (benzene), itself prepared from para-piperidino benzaldehyde. 3. 3-chloro-4-piperidino phenylalanine, hemihydrate, M.P. (MK) l83l86 C (C l-l Old/H O), starting from 2-phenyl-4-(3-chloro-4-piperdino benzylidene)- 5-oxazolone, M.P. (K) 140 C (cyclohexane), itself prepared from 3-chloro-4-piperidino benzaldehyde. 4. Para-(S-azabicyclo [3,3,0] oct-3-yl) phenylalanine, M.P. (MK) of its dihydrochloride 350C (isopropanol), starting from 2-phenyl-4-[para-(3- azabicylo [3,3,0] oct-3-yl) benzylidenel-S oxazolone, M.P. (K) 213 C (tetrahydrofuran), itself prepared from para-3-azabicylo [3,3,0] oct-3-yl) benzaldehyde. 5. 3-trifluoromethyl-4-[3-azabicylo [3,3,0] oct- 3-yl] phenylalanine, M.P. (M.K) 15415t 3 C(HzO), starting from 2-phenyl-4-[3-trifluoromethyl-4-(3- azabicyclo [3,3,0] oct-3-yl) benzylidene]-5-oxazolone, M.P. (K) 175 C (acetone), itself prepared from 3- trifluoromethyl-4-(3-azabicyclo [3,3,0] oct-3-yl) benzaldehyde. We claim: 1. A compound selected from the group consisting of (A) phenylalanine compounds of the general formula: Het Q CH2 ('I'H COOH

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (0)

    Publication numberPublication dateAssigneeTitle

NO-Patent Citations (3)

    Title
    Abshire, Chemical Abstracts, Vol. 70, Abstract No. 47822e, (1970), QDIA51
    Bergel et al., Chemical Abstracts, Vol. 53, columns 12202-12203, (1959), QDIA51
    Harper et al., Chemical Abstracts, Vol. 45, column 7193, (1951), QDIA51

Cited By (22)

    Publication numberPublication dateAssigneeTitle
    US-2008118464-A1May 22, 2008Ambrx, Inc.Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides
    US-2008177027-A1July 24, 2008Ambrx, Inc.Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides
    US-2008182969-A1July 31, 2008Ambrx, Inc.Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides
    US-2008187491-A1August 07, 2008Ambrx, Inc.Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides
    US-2010120686-A1May 13, 2010Ambrx, Inc.Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
    US-2011118450-A1May 19, 2011Ambrx, Inc.Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
    US-2011118451-A1May 19, 2011Ambrx, Inc.Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
    US-2011118501-A1May 19, 2011Ambrx, Inc.Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
    US-2011124880-A1May 26, 2011Ambrx, Inc.Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
    US-8008456-B2August 30, 2011Ambrx, Inc.Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
    US-8048988-B2November 01, 2011Ambrx, Inc.Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
    US-8071809-B2December 06, 2011Ambrx, Inc.Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
    US-8153758-B2April 10, 2012Ambrx, Inc.Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
    US-8367612-B2February 05, 2013Ambrx, Inc.Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
    US-8399614-B2March 19, 2013Ambrx, Inc.Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
    US-8557781-B2October 15, 2013Ambrx, Inc.Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
    US-8791231-B2July 29, 2014Ambrx, Inc.Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
    US-8809511-B2August 19, 2014Ambrx, Inc.Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
    US-8859802-B2October 14, 2014Ambrx, Inc.Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
    US-8865658-B2October 21, 2014Ambrx, Inc.Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
    US-9586988-B2March 07, 2017Ambrx, Inc.Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
    US-9637441-B2May 02, 2017Ambrx, Inc.Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides